SDAI Limited (the “Company”, and together with its subsidiaries the “Group”) is a limited liability company, incorporated and domiciled in Singapore, and was listed on the Catalist board of the SGX-ST on 22 July 2011.
The Group’s strategic focus is on the application of biotechnology to develop and provide anti-ageing, longevity and biological age management solutions. Through its biological age management and longevity platform SDAI BioAge™, the Group is building a science-led healthy longevity platform that connects longevity science, scientific expertise, health technologies and real-world consumer applications, with the aim of translating emerging research into practical products, services and long-term health management solutions. The Group intends to launch the SDAI BioAge™ Core, a biological age management supplement with controlled-release Calcium Alpha-Ketoglutarate as its core ingredient, in the fourth quarter of 2026. Developed from Professor Brian Kennedy’s proprietary formula, the SDAI BioAge™ Core is customised for the Asian populations with specific male and female formulations. Professor Brian Kennedy is the Chief Scientist of the “Maximising Healthy and Successful Longevity” grand challenge, which was launched by the National Research Foundation, in partnership with the Ministry of Health in May 2026 under Singapore’s $37 billion five-year Research, Innovation and Enterprise 2030 plan, Distinguished Professor in the Departments of Biochemistry and Physiology at the Yong Loo Lin School of Medicine, National University of Singapore (“NUS Medicine”), Director of the Centre for Healthy Longevity at the National University Health System, Programme Director of the Healthy Longevity Translational Research Programme at NUS Medicine, as well as Director of the NUS Bia-Echo Asia Centre for Reproductive Longevity and Equality.
In addition, the Group has expanded its offerings of other healthcare-related products and services. In December 2025, the Group launched the Bluecode Biotech B-III skincare series (“B-III Series”), an advanced line of plant stem cell-based skincare products. Developed by the Group’s in-house research team, the B-III Series integrates advanced bioengineering with next generation plant stem cell technology to meet the increasing global demand for science-driven anti-aging and regenerative skincare.
In January 2026, the Group also entered into a joint venture with Hubei Qiai Group Co., Ltd. to develop an international operations platform to expand the markets for mugwort and moxibustion-related products across the ASEAN region.
As the Group shifted its focus to the commercialisation of its longevity and biological age management solutions and other healthcare-related products and services, it has since significantly reduced its business of distributing high-end kitchen systems and appliances.
The Group’s role extends beyond introducing individual products or technologies. It seeks to connect scientific research, product innovation, health management and commercial application. By continuously engaging with developments in global longevity science and combining them with the health needs, lifestyles and market characteristics of Asian consumers, the Group aims to bring credible and commercially sustainable healthy longevity solutions to markets across Asia